Emi Caywood
Has grant
Director, Transplant and Cellular Therapy
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Nemours NCI Community Oncology Research Program (NCORP)
Open Date: 2014-08-01
Close Date: 2025-07-31
Articles (10)
Year:
2026
Chronic graft-versus-host-disease (cGVHD) is the primary nonrelapse limitation to a successful hematopoietic cell transplantation and is largely treated as a single biological entity. We hypothesized that there exist different biological subtypes of cGVHD. Using the Applied Biomarkers of Late Effects of Childhood Cancer (ABLE) network database, which is derived from the largest pediatric cGVHD cohort worldwide, we applied clustering analysis to subtype patients with cGVHD from the ABLE1.0 and 2.0 studies (51 patients with cGVHD and 158 with non-cGVHD). We found 3 distinct cGVHD subtypes: cGVHD-1 was characterized by an effector memory T-cell, cytotoxic natural killer cell, and early precursor B-cell predominant pattern; cGVHD-2 was phosphatidylcholine, cytokine, and plasma cell predominant; and cGVHD-3 had more naïve CD4+ T cells and naïve regulatory T cells, had later onset, and was the only subtype with measurable T-cell receptor excision circles. We partially replicated these subtypes using metabolomic data from a separate pediatric cohort of the Children’s Oncology Group trial ASCT0031 (33 patients with cGVHD and 39 with non-cGVHD). Furthermore, cGVHD-1 was associated with serotherapy (predominantly antithymocyte globulin) exposure, and cGVHD-3 was associated with receiving peripheral blood stem cells from donors, total body irradiation, and no previous acute GVHD. cGVHD-2 was associated with liver involvement and cGVHD-2 and -3 with de novo cGVHD. Overall, none of the subtypes were closely associated with organ involvement. Contrasting each subtype against patients with non-cGVHD, the 3 subtypes shared common markers, all of which were used in our previous cGVHD diagnostic classifier. These findings suggest the presence of distinct biological subtypes of cGVHD that may help guide therapeutic strategies.
Year:
2026
PURPOSE The objective was to identify factors associated with self-reported symptom burden measured using Symptom Screening in Pediatrics Tool (SSPedi) in pediatric patients with cancer. METHODS This was a secondary analysis of a cluster randomized trial enrolling pediatric patients newly diagnosed with cancer. Twenty sites were randomized to routine symptom screening versus usual care. Intervention included thrice-weekly symptom screening with SSPedi, delivery of severely bothersome scores to health care teams, and implementation of locally adapted symptom management care pathways. Primary outcome was total SSPedi scores, 0 (no bothersome symptoms) to 60 (worst bothersome symptoms), obtained at baseline, week four, and week eight in 430 patients (n = 217 intervention and n = 213 usual care). We created a mixed linear regression model evaluating design (including time point), patient/guardian, and site characteristics for their associations with symptom burden after controlling for treatment assignment. RESULTS SSPedi scores were significantly lower at weeks 4 and 8 compared with baseline ( P < .0001 overall), and at intervention versus control sites ( P < .0001). In the full model, males (estimate, –3.3 [95% CI, –4.6 to –2.0]; P < .0001) and sites with higher physician staffing ratios (each physician full-time equivalent per 100 new diagnoses estimate –0.20 [95% CI, –0.5 to 0.0]; P = .024) had significantly lower total SSPedi scores. CONCLUSION Total symptom burden was reduced by time, intervention (symptom screening and care pathways), and greater physician staffing ratio. Females had higher symptom burden. These data may inform programmatic implementation of routine symptom screening in pediatric patients with cancer.
Year:
2025
Cytomolecular features critical for risk-stratified treatment determination in pediatric acute myeloid leukemia (AML) were expanded in Children’s Oncology Group (COG) Phase III trial AAML1831 based on previous trials. It remains unknown whether the cytomolecular risk profiles are generalizable to the real-world. We addressed this knowledge gap using a nationally representative real-world cohort of 913 pediatric AML patients. Distributions of cytomolecular risk profiles and individual markers were comparable for trial-enrolled and non-enrolled patients, as well as across social drivers of trial enrollment (race/ethnicity, language, insurance, acuity). Compared to patients with only favorable cytomolecular markers (4-year overall survival [OS] = 89.48%; 95% CI = 84.46% to 92.95%), patients with both favorable and unfavorable (hazards ratio [HR] = 2.49, 95% CI = 1.18 to 5.23), neutral (HR = 4.33, 95% CI = 2.75 to 6.82), and only unfavorable (HR = 5.80, 95% CI = 3.70 to 9.11) markers all had increased hazards of death. Cytomolecular risk informed by trial data appears to be generalizable to the real-world setting in pediatric AML.
Year:
2025
Purpose: The combination of gemcitabine and docetaxel is often used to treat patients with recurrent osteosarcoma. Nab-paclitaxel has preclinical activity against osteosarcoma and is potentially less myelosuppressive than docetaxel. We conducted a prospective multi-institutional phase II trial combining gemcitabine and nab-paclitaxel for patients aged 12 to 30 years with recurrent osteosarcoma and measurable disease. Patients and Methods: A Simon’s two-stage design was used to test a 4-month progression-free survival (PFS-4) of 10% vs. 35%. Patients received nab-paclitaxel 125 mg/m 2 and gemcitabine 1,000 mg/m 2 weekly × 3 in 4-week cycles. Immunohistochemical analysis of archival tissue and serial assessment of circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) using ultralow passage whole-genome sequencing were performed to identify potential biomarkers of response. Results: Eighteen patients received 56 total cycles (median 2, range 1–12). Two patients (11%) experienced confirmed partial response and six (33%) received >2 cycles. The PFS-4 was 28% (95% confidence interval, 13%–59%). Six patients required dose reductions and three patients were removed due to toxicities. All 18 patients had detectable CTCs and 10 had ctDNA identified. All eight patients with MYC amplification at study entry experienced disease progression. Conclusions: Gemcitabine and nab-paclitaxel demonstrated similar clinical activity and toxicity compared to previous retrospective reports utilizing gemcitabine and docetaxel in patients with recurrent osteosarcoma. Serial analysis of CTC and ctDNA was feasible in this prospective multi-institution study and provides preliminary data on the use of these assays in patients with relapsed disease.
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Collaborators (27)
Eneida Nemecek
Professor
Oregon Health & Science University
Eric Sandler
Department Chair
Nemours Children's Health System
Christine A Pratilas
Vice Chair for Pediatric Oncology
Johns Hopkins University School of Medicine
David Loeb
Professor
Albert Einstein College of Medicine
Javier Oesterheld
Clinical (Full) Professor
Wake Forest University
Yimei Li
University of Pennsylvania
Masanori Hayashi
Assistant Professor
University of Colorado Boulder
Ramamoorthy Nagasubramanian
Stanford University
Maria Gramatges
Baylor College of Medicine
Leo Mascarenhas
Division Chief and Director, Pediatric Hematology-Oncology, Guerin Children's; Director, Sarcoma Program, Cedars-Sinai Cancer
Cedars-Sinai Medical Center
Catherine Aftandilian
Stanford University School of Medicine
Gary Hettinger
Assistant Professor
NYU Langone Health
Jun Yin
Associate Professor
H Lee Moffitt Cancer Center and Research Institute
Jeffrey Huo
Clinical Assistant Professor
Wake Forest School of Medicine
Melissa P. Beauchemin
Assistant Professor of Nursing
Columbia University Irving Medical Center
Brooke Fridley
Director
Children's Mercy Hospital
Scott Bradfield
Interim Division Chief
Nemours Children's Health System
Jeffrey Davis
Clinical Associate Professor
The University of British Columbia
Matteo Trucco
Associate Professor
Cleveland Clinic
Alix Seif
Associate Professor
University of Pennsylvania
Scott Borinstein
Professor
Vanderbilt University Medical Center
Sung Choi
MD / Associate Professor
University of Michigan Hospital
Blachy Dávila Saldaña
Associate Professor
Cincinnati Children's Hospital Medical Center
Lars Wagner
division of pediatric hematology‐oncology duke university medical center durham north carolina usa
Andrew Harris
Associate Attending
Memorial Sloan Kettering Cancer Center
Nataliya Buxbaum
Assistant Professor of Oncology
Roswell Park Comprehensive Cancer Center
Christopher Dvorak
University of California, San Francisco
Make your next move.
Prepare your application
Review drafts before you send them.